Drug-induced cardiotoxicity is emerging as an important issue among cancer survivors. For
several decades, this topic was almost exclusively associated with anthracyclines, for which …

Human epidermal growth factor receptor 2 (HER2) gene amplification or protein
overexpression occurs in 20% to 25% of breast tumors, often leading to an aggressive …

Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast
Cancer Page 1 Nomogram to Predict Subsequent Brain Metastasis in Patients With …

Approximately 20% of new diagnosed breast cancers overexpress the human epidermal
growth factor receptor 2 (EGFR2), also known as erythroblastic leukemia viral oncogene …

The cardiotoxic synergism resulting from the sequential treatment with anthracyclines and
trastuzumab has been attributed to the trastuzumab-induced loss of the erbB2-related …

INTRODUCTION: HER-2 over-expression is implicated in the pathogenesis of breast cancer
and represents a key marker and determinant of patient outcome. Trastuzumab/Herceptin …

Introduction Improvement in cancer survival rates have increased longevity but have also
revealed physical and psycho-social sequelae of long-term survivorship and raised many …

Recent updated reports from the large adjuvant trials in HER2-positive breast cancer
indicate that the remarkable benefits of adding trastuzumab to chemotherapy appear, so far …

Cancer is increasingly recognized as “miscommunication” disease, in which inter-and
intracellular signals are aberrantly sent and/or received, resulting in the uncontrolled …

Résumé Le cancer du sein HER2-positif représente 20 à 25% de l'ensemble des cancers du
sein. La surexpression de ce récepteur tyrosine-kinase est classiquement associée à un …